JP2024526944A5 - - Google Patents

Info

Publication number
JP2024526944A5
JP2024526944A5 JP2024503869A JP2024503869A JP2024526944A5 JP 2024526944 A5 JP2024526944 A5 JP 2024526944A5 JP 2024503869 A JP2024503869 A JP 2024503869A JP 2024503869 A JP2024503869 A JP 2024503869A JP 2024526944 A5 JP2024526944 A5 JP 2024526944A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
interleukin
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526944A (ja
Filing date
Publication date
Priority claimed from GBGB2110721.4A external-priority patent/GB202110721D0/en
Priority claimed from GBGB2110862.6A external-priority patent/GB202110862D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/070974 external-priority patent/WO2023006765A1/en
Publication of JP2024526944A publication Critical patent/JP2024526944A/ja
Publication of JP2024526944A5 publication Critical patent/JP2024526944A5/ja
Pending legal-status Critical Current

Links

JP2024503869A 2021-07-26 2022-07-26 アルコール性肝疾患の処置および予防 Pending JP2024526944A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2110721.4 2021-07-26
GBGB2110721.4A GB202110721D0 (en) 2021-07-26 2021-07-26 Treatment and prevention of alcoholic liver disease
GBGB2110862.6A GB202110862D0 (en) 2021-07-28 2021-07-28 Treatment and prevention of alcoholic liver disease
GB2110862.6 2021-07-28
PCT/EP2022/070974 WO2023006765A1 (en) 2021-07-26 2022-07-26 Treatment and prevention of alcoholic liver disease

Publications (2)

Publication Number Publication Date
JP2024526944A JP2024526944A (ja) 2024-07-19
JP2024526944A5 true JP2024526944A5 (cg-RX-API-DMAC7.html) 2025-07-14

Family

ID=83081349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503869A Pending JP2024526944A (ja) 2021-07-26 2022-07-26 アルコール性肝疾患の処置および予防

Country Status (4)

Country Link
US (1) US20250092126A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376948A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024526944A (cg-RX-API-DMAC7.html)
WO (1) WO2023006765A1 (cg-RX-API-DMAC7.html)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
WO2020152122A1 (en) * 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방

Similar Documents

Publication Publication Date Title
JP2022521591A5 (cg-RX-API-DMAC7.html)
JP2022531591A5 (cg-RX-API-DMAC7.html)
Tanaka et al. Interleukin (IL-6) immunotherapy
Maes et al. Targeting interleukin-4 in asthma: lost in translation?
Villaescusa et al. A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
JP2020510662A5 (cg-RX-API-DMAC7.html)
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
JP2020128375A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2019534891A5 (cg-RX-API-DMAC7.html)
JP2010500360A5 (cg-RX-API-DMAC7.html)
Hirota et al. Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys
Rommasi et al. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
Clark et al. Potential of anticytokine therapies in central nervous system ischaemia
KR20060023968A (ko) 중증 급성 호흡기 증후군(sars)의 치료를 위한 조성물및 방법
AU2019236656A1 (en) Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
CN106459971B (zh) 用于治疗自身免疫性疾病的联合疗法
JP2013504603A5 (cg-RX-API-DMAC7.html)
Crockett et al. Protection of early phase hepatic ischemia-reperfusion injury by cholinergic agonists
US20240024308A1 (en) Tlr7/8 antagonists for the treatment of coronavirus infections
Nishimoto Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan
CN105705518A (zh) 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP2022518251A5 (cg-RX-API-DMAC7.html)
JP2022549854A5 (cg-RX-API-DMAC7.html)
NZ728020A (en) Anti-il4-il 13 bispecific antibodies
Ramos et al. Targeting specific immunologic pathways in Crohn's disease